• <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置首页>技术资料首页>行业动态>新品动态>Gyros与DI Biotech公司签署韩国市场生物技术药物合作开发协议

    Gyros与DI Biotech公司签署韩国市场生物技术药物合作开发协议

    Gyros2010年1月7日 13:36 点击:2817

    瑞典Gyros AB
    Gyros与DI Biotech公司签署韩国市场生物技术药物合作开发协议。前者拥有独?#19994;?#30333;质药物开发平台,已经拥有中国欧洲和美国合作方,并将韩国作为其拓展亚洲市场的第一站。

    新加坡,2009年11月27日:Gyros,一个自动化的微型治疗开发免疫测定蛋白质顶端发展商直接签订了生物技术的领先供应商,韩国生命科学市场分销协议。根据该协议,直接投资的市场和生物技术将Gyros提供的专有技术,Gyrolab,全力支持韩国制药,生物技术,临床试验和委外制造(CMO)产业。

    Gyros说Gyrolab已迅速成为为高的生物?#21697;ǎ?#21457;展业绩建立免疫检测的首选技术。该技术越来越多地利用领先的制药和生物技术公司,他们的承包服务组织,在其发展过程和药物临床试验,在欧洲和美国。由于这一成功,该公司已决定扩大在亚洲的业务,与韩国,作为其最初的市场。

    “我们很高兴能代表直接投资的生物技术在韩国市场的产品”,国家埃里克Walldén,首席执行官兼总裁的Gyros。 “这是一个长期的经验,存在的组织,作为一个高科技工具的领先供应商,生物技术市场。韩国致力于?#27426;显?#38271;的生物?#21697;ǎ?#21457;展领域,我们期待着能够稳固的地位提供各种技术进行中的倡议在这个国家,“他说。
    东南金,首席执行官兼总裁直接生物评论:“我们已经参加过在韩国Gyrolab的市场,反应是迅速和积极的,这是非常令人鼓舞的。Gyrolab提供好处,在药物开发的各阶层的认识,以及在政府资助的机构。制药,生物技术,特别是快速增长的临床研究机构和奇美电子公司,?#25216;?#21040;的可能性,不仅斜了生产力,而且要提高他们的竞争力。这些行业的财务状况已经很强,并与韩国政府的1.5亿美元相当于最近的投资,以进一步推动加上内的智能工程'的生物?#21697;?#30340;发展,我们感到非常乐观的迅速崛起和在韩国Gyrolab执行。“

    Gyros新闻稿
    Gyros and DI Biotech sign distribution agreement for the Korean market

    Gyros® AB, the leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the signing of a distribution agreement with DI Biotech, the leading supplier to the Korean life-science market. Under the terms of the agreement, DI Biotech will market and provide full support for Gyros' proprietary technology, Gyrolab®, to the Korean pharmaceutical, biotech, CRO and CMO industries.

    Gyrolab has rapidly become established as the preferred technology for high-performance immunoassays for the development of biotherapeutics. The technology is increasingly employed by leading pharmaceutical and biotech companies, and their contracted service organizations, in their drug development process and clinical trials, in both Europe and the USA. As a result of this success, the company has now decided to expand its business into Asia, with Korea as its initial market.

    "We are very happy to have DI Biotech representing our products in the Korean market", states Erik Walldén, CEO and President of Gyros. "It's an organization with longstanding experience, presence, and a solid position as a leading supplier of high-tech tools to the biotech market. Korea is committed to the growing biotherapeutics development segment and we are looking forward to supplying enabling technology to various ongoing initiatives in the country," he concludes.

    S. E. Kim, CEO and President at DI Biotech comments: "We have already tested the market for Gyrolab in Korea, and the response was immediate and positive, which was very encouraging. The benefits that Gyrolab provides are recognized in all sectors of pharmaceutical development, as well as in government-funded institutes. Pharma, biotech and especially, the fast-growing CRO and CMO companies, all see possibilities, to not only ramp-up productivity, but also to boost their competitiveness. The financial standing of these industries was already strong, and coupled with the Korean government's recent investment of the equivalent of 90 million EUR, to further propel the development of biotherapeutics within the 'SMART project', we are extremely optimistic about the rapid uptake and implementation of Gyrolab in Korea."

     

    For further information, please contact:
    Erik Walldén, CEO
    Tel: +46 18-56 64 00
    [email protected]

    Press relations
    Linda van Manen, BGA Group
    Tel: +31 78 631 97 15
    [email protected]

     

    Notes to editors:
    About Gyros AB
    Gyros is the world leader in automated micro-immunoassays for therapeutic protein development.

    Gyrolab, the company's automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. The ease of assay transfer is unsurpassed in the industry.

    Gyrolab enables assays to be conducted with a significantly reduced background, four-log dynamic range and with higher throughput. All this is achieved using only nanoliter volumes of critical reagents and sample. More data can be generated in less time and with higher precision, consequently improving productivity and efficiency. Applications span the entire spectrum for immunoassays and Gyrolab is now firmly established as the preferred solution for pharmacokinetic (PK) assays in the development of therapeutic proteins.

    Many major pharmaceutical companies and service providers - CMOs/CROs - have already implemented multiple Gyrolab platforms to boost their drug development process and to meet increasing regulatory demands on testing. Several validated assays are already in some phase of clinical sample analysis. Gyrolab xP complies with the requirements of 21 CFR part 11 and comprehensive validation support is provided.

    The company has over 50 employees based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe.

    About DI Biotech Ltd.
    DI Biotech Ltd. is headquartered in Seoul, Korea, and has a branch office in Daejeon City. The company was spun off from Pharmacia Biotech Korea and in 1997 became established as an affiliated company of DI Corp, which is listed on the Korean Stock exchange. DI Biotech has been a market leader and pioneer in Korea's Life Science market. The company works closely with its customers, with a focus on three research areas: genomics, molecule-interaction, and cell imaging.
     

    (来源: Gyros )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://www.67994619.com,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权?#20219;?#39064;,请在作品发表之日起一周内与本网联系,否则视为?#29260;?#30456;关权利。


    云南11选5技巧
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
  • <div id="y09gn"></div>
  • <li id="y09gn"></li>
    <dl id="y09gn"></dl>
    <div id="y09gn"><s id="y09gn"></s></div>
    3d彩票高手计划 吉林快三开奖直播平台 七乐彩开奖号 香港六合彩天线宝宝 贵州11选5中奖 打死都不赌分分彩 宁夏11选5任选走势图 2018最新送现金的棋牌 18选7一等奖多少钱 三人斗地主规则说明 快乐12复式表 湖北11选5跨度 青海11选5前三直遗漏 彩票在线生成器 梭哈扑克牌怎么下载